FDA - Food and Drug Administration

11/17/2026 | Press release | Distributed by Public on 11/17/2026 14:47

November 17, 2026 - FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

For Immediate Release: November 17, 2026

The U.S. Food and Drug Administration today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world. The GRDP marks a major step forward in the FDA's global leadership and may accelerate patient access to innovative therapies throughout the world.

The GRDP enables the FDA to more efficiently share minimally redacted approval packages, including the FDA's detailed scientific and regulatory assessments, directly with companies who can then share them with regulatory authorities outside of the United States, empowering those authorities to rely on the FDA's rigorous, science-based review decisions rather than conducting duplicative and time-consuming product evaluations of their own, while maintaining sovereignty over their regulatory decision.

"The GRDP is a prime example of America First policies improving public health worldwide," said Grace Graham, FDA Deputy Commissioner for Policy, Legislation, and International Affairs. "The FDA is the global gold standard and making it easier for applicants to leverage our detailed scientific assessments to facilitate faster access for patients everywhere is an example of America's continued interest in advancing global health under the Trump Administration."

The GRDP launched on Oct. 30, with a President's Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug indicated for both HIV prevention and treatment. This is an especially meaningful starting point given PEPFAR's life-saving mission to combat HIV/AIDS in some of the world's most vulnerable populations. The GRDP is currently available to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. However, the FDA intends to expand the GRDP in January 2027 to all novel drug and biologics (New Molecular Entity New Drug Applications and 351(a) Biologics License Applications), dramatically broadening the program's reach and impact.

The FDA also intends to launch a pathway in early 2027 to expedite an applicant's ability to request their minimally redacted action packages for approved and licensed drugs and biologics, accelerating global access to medicines that are already on the market in the United States and have been found to be safe and effective by the FDA.

To receive a minimally redacted application approval package as part of the GRDP, applicants must request to participate within 10 calendar days of approval and confirm the application package is being submitted to a foreign regulatory authority in support of a marketing application. Applicants with eligible GRDP applications will receive detailed information in FDA approval letters and the agency intends to provide the minimally redacted package on an expedited basis. Requests for minimally redacted approval packages for other purposes will not be processed under the GRDP and should be submitted as a Freedom of Information Act (FOIA) request.

"In an era of increasing global interdependence in pharmaceutical development and supply chains, the FDA's leadership is most effective when it is collaborative," said Mark Abdoo, FDA Associate Commissioner for Global Policy and Strategy. "The GRDP reflects a forward-looking vision of regulatory leadership: one defined not by exclusivity, but by the willingness to share expertise, elevate global standards, and put patients first - wherever they are."

The GRDP addresses one of the most persistent and consequential challenges in global health: the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. When a drug is approved by the FDA, patients in many parts of the world may wait months or years longer for their own national health authority to complete an independent review due to limited regulatory capacity and resources.

Beyond individual product approvals, the GRDP supports global health security. Harmonized regulatory decisions reduce the risk of fragmented or inconsistent product standards across markets, helping to ensure that the same high-quality therapies reach patients regardless of where they live, including here in the United States.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

###


FDA - Food and Drug Administration published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 20:47 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]